N@N

HAYWARD, Calif. & FORT COLLINS, Colo.--([ BUSINESS WIRE ])--Impax Laboratories, Inc.(NASDAQ: IPXL) and TOLMAR, Inc. today announced that they will collaborate on a multiproduct agreement for the development, supply and distribution of alternative dosage form products. The targeted products had over $1 billion in brand sales in 2011, with several of the products having first-to-file or first-to-market potential. The products and terms of the agreement were not disclosed.

"In the past two years, we have entered into four distinct partnerships for alternative dosage form products as we continue to execute our strategy of diversifying our product base. Our business development activities will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms."

aWe are excited to expand our relationship with TOLMAR on these products. It represents an ideal extension of our initial product agreement,a said Larry Hsu, Ph.D., president and CEO of Impax Laboratories. aIn the past two years, we have entered into four distinct partnerships for alternative dosage form products as we continue to execute our strategy of diversifying our product base. Our business development activities will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms.a

Mike Duncan, CEO of TOLMAR, said: aWe are very pleased with this agreement. TOLMAR is once again recognized as a key player in the Specialty Pharma space. This agreement is aligned with our long term corporate strategy and we firmly believe that Impax Laboratories is the right partner for these products. From its inception in 2006, TOLMAR has been growing at a very impressive rate developing and introducing several new products to the market. TOLMAR is continuously expanding its facilities and employee base to meet current and future needs.a

About Impax Laboratories, Inc.

Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals Division and markets third-party branded products through the Impax Pharmaceuticals Division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward, Philadelphia and Taiwan facilities. For more information, please visit the Company's Web site at: [ www.impaxlabs.com ].

About TOLMAR, Inc.

TOLMAR, Inc. is a northern Colorado based pharmaceutical research, development, manufacturing and commercial operations company. TOLMAR develops and manufacturers both proprietary and generic pharmaceutical products. TOLMAR provides its customers with a competitive and sustainable combination of product development and commercial services. The companyas strengths include a proven development, clinical, regulatory and manufacturing infrastructure with a highly trained and experienced staff. Several of its marketed products are still in an early stage growth mode. TOLMAR products are commercialized through marketing partners in over fifty five countries worldwide, including North America and Europe.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the Companyas future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the effect of current economic conditions on the Companyas industry, business, financial position and results of operations, fluctuations in the Companyas revenues and operating income, the Companyas ability to successfully develop and commercialize pharmaceutical products, reductions or loss of business with any significant customer, the impact of consolidation of the Companyas customer base, the impact of competition, the Companyas ability to sustain profitability and positive cash flows, any delays or unanticipated expenses in connection with the operation of the Companyas Taiwan facility, the effect of foreign economic, political, legal and other risks on the Companyas operations abroad, the uncertainty of patent litigation, increased government scrutiny on the Companyas agreements with brand pharmaceutical companies, consumer acceptance and demand for new pharmaceutical products, the difficulty of predicting Food and Drug Administration filings and approvals, the Companyas inexperience in conducting clinical trials and submitting new drug applications, the Companyas ability to successfully conduct clinical trials, the Companyas reliance on third parties to conduct clinical trials and testing, the availability of raw materials and impact of interruptions in the Companyas supply chain, the use of controlled substances in the Companyas products, disruptions or failures in the Companyas information technology systems and network infrastructure, the Companyas reliance on alliance and collaboration agreements, the Companyas dependence on certain employees, the Companyas ability to comply with legal and regulatory requirements governing the healthcare industry, the regulatory environment, the Companyas ability to protect the Companyas intellectual property, exposure to product liability claims, changes in tax regulations, the Companyas ability to manage the Companyas growth, including through potential acquisitions, the restrictions imposed by the Companyas credit facility, uncertainties involved in the preparation of the Companyas financial statements, the Companyas ability to maintain an effective system of internal control over financial reporting, any manufacturing difficulties or delays, the effect of terrorist attacks on the Companyas business, the location of the Companyas manufacturing and research and development facilities near earthquake fault lines and other risks described in the Companyas periodic reports filed with the Securities and Exchange Commission.Forward-looking statements speak only as to the date on which they are made, and Impax undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.